Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the ?? IL2 receptor complex (IL2R??) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the ??? IL2 receptor complex (IL2???) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells.

Abstract: Among the various aspects of the present disclosure relates to methods and compositions useful in convert inflammatory dietary fatty acids (omega 6) to anti-inflammatory fatty acids (omega 3). Specifically, the present disclosure provides methods and compositions for increasing n-3 desaturase expression or activity in a subject. The disclosure provides various compositions for providing increased n-3 desaturase expression or activity including a variety of viral vector and engineered microorganisms. The disclosure provides, in part, methods for reducing local and/or systemic inflammation, improving wound healing, preventing premature cellular senescence, treating or preventing a disease, disorder, or condition related to inflammation or obesity and treating or preventing arthritis.

Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: The present invention relates to uses of threonyl-tRNA synthetase (TARS) derived from Akkermansia muciniphila or a fragment thereof as an active ingredient for prevention, alleviation, and treatment of an inflammatory disease. The Akkermansia muciniphila TARS or a fragment thereof according to the present invention promotes the differentiation of M2 macrophages, which are anti-inflammatory macrophages, to multiply macrophages, thereby increasing the secretion of IL-10 as an anti-inflammatory cytokine, leading to the proliferation of B cells to result in an anti-inflammatory effect, and thus was verified to show alleviation effects of not only inflammatory diseases but also immune diseases, infectious diseases, and metabolic diseases accompanied by inflammation, and to have excellent effects in the prevention or treatment of an inflammatory bowel disease (IBD).

Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

Abstract: Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self-destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.

Abstract: Disclosed are a Weissella cibaria GSKM06 strain and the use thereof. The strain is safe because it has no toxicity to the human body and has excellent physiological activities such as suppression of inflammatory reactions as well as immunomodulatory effects, thus being useful as a substance to treat immune hypersensitivity (allergic diseases such as skin, asthma and rhinitis), normalize immunity, and prevent, ameliorate or treat inflammatory diseases.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: A pharmaceutical composition effective for the prevention or treatment of atopic disease is disclosed. The pharmaceutical composition contains a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect for atopic disease, the pharmaceutical composition of the present invention exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Abstract: Provided are an Anaerostipes sp. B2131 strain and an application thereof in inflammatory bowel diseases. The Anaerostipes sp. B2131 strain has a deposit number of CGMCC NO. 1.5.5295. The Anaerostipes sp. B2131 strain is used for regulating the homeostasis of intestinal flora, and preventing and treating the occurrence of an intestinal disease such as an inflammatory bowel disease.

Abstract: The disclosure discloses a strain of Bifidobacterium breve capable of preventing and relieving psoriasis and application thereof, belonging to the field of microbial technologies and medical technologies. The disclosure provides new uses of B. breve CCFM1078 in inhibiting the release of IL-23/Th17 axis related inflammatory factors, and relieving the psoriasis. The B. breve CCFM1078 of the disclosure can relieve the lesion skin of psoriasis-like mice, and can inhibit thickening of the skin epidermal layer, so that the IL-23 level, the IL-22 level and the IL-17 level in the skin decrease by 20.3%, 22.0% and 18.3%, respectively. The B. breve CCFM1078 has a great application prospect in the preparation of a product (such as a food, a drug or a health food) for preventing and/or treating psoriasis.

Abstract: Immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cell.

Abstract: Methods of storage and preservation of photosynthetically active cells and photosynthetic biomaterials are provided herein. Contemplated methods comprise storing the cells and biomaterials at a refrigeration temperature, optionally without light. The stored cells and biomaterials may be placed in a nitrogen containing medium under illumination before use. The chlorophyll content, oxygen consumption rate, oxygen production rate and/or morphology may be substantially preserved throughout the storage and awakening process.

Abstract: The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).

Abstract: Novel bispecific and multispecific antibodies having differentially modified light chains, that allows for isolation of the bispecific or multispecific antibodies based on a differential affinity towards an affinity reagent.

Abstract: This invention relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments in a subject in need thereof. This invention also relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments induced by sleep deprivation and/or insufficient sleep in a subject in need thereof.

Abstract: Aspects of the disclosure relate to novel scFv molecules that are useful for incorporation into novel chimeric antigen receptors with enhance anti-tumor activity. Further aspects relate to a polypeptide comprising a CAR comprising, in order from amino proximal to carboxy proximal end, a scFv, a transmembrane domain, a torsional linker, and a cytoplasmic region comprising a primary intracellular signaling domain, wherein the torsional linker comprises 1-12 alanine residues. Also described are nucleic acids comprising a sequence encoding a polypeptide of the disclosure, vectors, such as lentiviral vectors comprising the nucleic acids of the disclosure, cells comprising and/or expressing nucleic acids and/or polypeptides of the disclosure, and populations of cells comprising the cell embodiments of the disclosure. Also provided are methods of making cells that express a polypeptide and methods of treating patients with the polypeptides and cell compositions of the disclosure.

Abstract: The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet. In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet, especially to determine the likelihood that the dietary intervention may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

Abstract: A method for improving hepatic function, including administering an effective amount of a composition including a green tea-derived Lactiplantibacillus plantarum strain; a culture of the strain; a lysate of the strain; an extract of the strain; an extract of the culture; or an extract of the lysate to a subject in need thereof is disclosed in the specification.